Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01274429 · ClinicalTrials.gov registry record · Phase 1
Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01274429 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 5 participants.
The verdict
NCT01274429, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The goal of this study is to produce a new treatment that would benefit adult subjects by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance). This project is designed to study the innovative idea that oral immunotherapy (OIT), the ingestion of small increasing amounts of food allergen, will desensitize subjects with peanut hypersensitivity by regulating their mucosal and systemic immune reactivity and cause long-term tolerance.
Interventions
- DRUG Peanut flour
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01274429
The ClinicalTrials.gov registry entry for NCT01274429 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peanut flour is the first listed.
NCT01274429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01274429 about?
NCT01274429 is a clinical study titled "Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults". The goal of this study is to produce a new treatment that would benefit adult subjects by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance). This project is designed to study the innovative ...
What is the current status of trial NCT01274429?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01274429?
The interventions under investigation include: Peanut flour (DRUG).
Who is sponsoring clinical trial NCT01274429?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.